Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-1777 in Atopic Dermatitis
NCT05432596Phase 2Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- May 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lepzacitinib in atopic dermatitis (AD) (6 arms), sponsored by Aclaris Therapeutics, Inc. Primary endpoint: Eczema Area and Severity Index Score at 4 weeks. Started May 2022; status: completed.
02
Drugs
lepzacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05432596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432596.